The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis

Saved in:
Bibliographic Details
Published inBlood Vol. 128; no. 1; pp. 138 - 140
Main Authors Leong, Darryl P., Caron, François, Hillis, Christopher, Duan, Annie, Healey, Jeff S., Fraser, Graeme, Siegal, Deborah
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 07.07.2016
Subjects
Agammaglobulinaemia Tyrosine Kinase
Animals
Atrial Fibrillation - chemically induced
Atrial Fibrillation - etiology
Humans
Incidence
Leukemia - drug therapy
Lymphoma - drug therapy
Protein Kinase Inhibitors - adverse effects
Protein Kinase Inhibitors - therapeutic use
Protein-Tyrosine Kinases - antagonists & inhibitors
Pyrazoles - adverse effects
Pyrazoles - therapeutic use
Pyrimidines - adverse effects
Pyrimidines - therapeutic use
Online AccessGet full text

Cover

Author Fraser, Graeme
Siegal, Deborah
Healey, Jeff S.
Hillis, Christopher
Caron, François
Leong, Darryl P.
Duan, Annie
Author_xml – sequence: 1
  givenname: Darryl P.
  surname: Leong
  fullname: Leong, Darryl P.
  email: leongd@phri.ca
  organization: The Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
– sequence: 2
  givenname: François
  surname: Caron
  fullname: Caron, François
  organization: The Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
– sequence: 3
  givenname: Christopher
  surname: Hillis
  fullname: Hillis, Christopher
  organization: Department of Oncology, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
– sequence: 4
  givenname: Annie
  surname: Duan
  fullname: Duan, Annie
  organization: The Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
– sequence: 5
  givenname: Jeff S.
  surname: Healey
  fullname: Healey, Jeff S.
  organization: The Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
– sequence: 6
  givenname: Graeme
  surname: Fraser
  fullname: Fraser, Graeme
  organization: Department of Oncology, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
– sequence: 7
  givenname: Deborah
  surname: Siegal
  fullname: Siegal, Deborah
  organization: Department of Medicine, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27247135$$D View this record in MEDLINE/PubMed
BookMark eNp9kE9LAzEQxYNUbKt-A5F8gegku9lNPQhS_AeCl148hdlkgtHtriRbpd_e1apHTwOP92bm_eZs0vUdMXYi4UxKo86btu-9UCArAVrUUhll9thMamUEgIIJmwFAJcpFLadsnvMLgCwLpQ_YVNWqrGWhZ-xp9Uw8xfzK-8BxSBFbHmKTYtviEPuOf8ThmY_CZohdbPgm0wVHnrd5oPXocDzRe6QPjp3naxpQYIftNsd8xPYDtpmOf-YhW91cr5Z34uHx9n559SBcCWYQvtTSOYSGHGoKuvJ1HUqnvFKLUIMhKQmVMajLQkIBoVqgR5QmGNeMwiErd2td6nNOFOxbimtMWyvBfoGy36DsFygL2u5AjbHTXext06zJ_4V-yYyGy52Bxt_HhslmF6lz5GMiN1jfx_8vfAJ5mH1M
CitedBy_id crossref_primary_10_1007_s00277_017_2982_1
crossref_primary_10_3390_cells11081338
crossref_primary_10_1038_s41375_018_0276_9
crossref_primary_10_1080_14656566_2019_1689959
crossref_primary_10_1182_bloodadvances_2016001883
crossref_primary_10_1186_s13045_018_0626_0
crossref_primary_10_1182_hematology_2020000121
crossref_primary_10_3389_fcvm_2021_758010
crossref_primary_10_1002_ajh_26367
crossref_primary_10_1007_s00277_024_05691_2
crossref_primary_10_1097_HS9_0000000000000692
crossref_primary_10_1016_j_jacep_2016_10_004
crossref_primary_10_1038_s41375_019_0592_8
crossref_primary_10_1182_blood_2017_05_737510
crossref_primary_10_1016_j_clml_2017_02_011
crossref_primary_10_1016_j_clml_2019_10_004
crossref_primary_10_1177_10781552231171925
crossref_primary_10_1097_MBC_0000000000000749
crossref_primary_10_1182_bloodadvances_2022007938
crossref_primary_10_1159_000500164
crossref_primary_10_1016_j_redox_2020_101432
crossref_primary_10_1111_jth_13651
crossref_primary_10_1182_asheducation_2017_1_338
crossref_primary_10_1080_10428194_2017_1315115
crossref_primary_10_1016_j_jacc_2017_09_1095
crossref_primary_10_26442_18151434_2021_2_200957
crossref_primary_10_1159_000529260
crossref_primary_10_1016_j_hoc_2020_06_007
crossref_primary_10_1080_10428194_2020_1864352
crossref_primary_10_1200_EDBK_279099
crossref_primary_10_3389_fphar_2018_01058
crossref_primary_10_1007_s11899_017_0369_y
crossref_primary_10_1111_bjh_14321
crossref_primary_10_1016_j_ejim_2017_09_025
crossref_primary_10_3390_jcm9092935
crossref_primary_10_1001_jamanetworkopen_2019_11838
crossref_primary_10_1111_ejh_13854
crossref_primary_10_1016_j_pharmthera_2018_04_009
crossref_primary_10_1182_bloodadvances_2017009720
crossref_primary_10_2147_DDDT_S377697
crossref_primary_10_1016_j_leukres_2016_08_004
crossref_primary_10_1007_s00508_019_1534_1
crossref_primary_10_1007_s11912_021_01102_1
crossref_primary_10_1038_s41598_023_47735_z
crossref_primary_10_1007_s11912_018_0691_0
crossref_primary_10_1016_j_jacc_2019_07_056
crossref_primary_10_1016_S0140_6736_18_30422_7
crossref_primary_10_3389_fcvm_2023_1113231
crossref_primary_10_1007_s11899_019_00512_0
crossref_primary_10_1182_blood_2016_10_742437
crossref_primary_10_1182_blood_2019002805
crossref_primary_10_4330_wjc_v16_i5_269
crossref_primary_10_1159_000452786
crossref_primary_10_1007_s40266_017_0468_4
crossref_primary_10_1080_15384047_2021_1980313
crossref_primary_10_20996_1819_6446_2021_12_11
crossref_primary_10_1007_s11936_019_0732_5
crossref_primary_10_1111_bcp_14440
crossref_primary_10_1182_blood_2019003893
crossref_primary_10_1016_j_soncn_2021_151177
crossref_primary_10_1016_j_clml_2020_02_001
crossref_primary_10_1111_bjh_17788
crossref_primary_10_1016_j_hoc_2018_05_012
crossref_primary_10_36660_abc_20201362
crossref_primary_10_1055_s_0041_1726298
crossref_primary_10_1093_ehjcvp_pvaa037
crossref_primary_10_15829_1728_8800_2020_2417
crossref_primary_10_1177_1078155218785983
crossref_primary_10_1016_j_procbio_2024_04_002
crossref_primary_10_1007_s11523_022_00895_w
crossref_primary_10_1007_s11912_019_0797_z
crossref_primary_10_1080_17474086_2020_1851184
crossref_primary_10_1002_hon_2770
crossref_primary_10_1016_j_critrevonc_2019_02_001
crossref_primary_10_1038_s41569_020_0348_1
crossref_primary_10_1177_20406207221116577
crossref_primary_10_1016_j_critrevonc_2021_103238
crossref_primary_10_1111_bjh_16209
crossref_primary_10_1016_j_jacc_2019_01_017
crossref_primary_10_1186_s40959_024_00237_x
crossref_primary_10_1182_blood_2023020013
crossref_primary_10_1007_s40266_019_00678_5
crossref_primary_10_1016_j_critrevonc_2024_104428
crossref_primary_10_1134_S1068162022060280
crossref_primary_10_5604_01_3001_0013_1683
crossref_primary_10_1080_17474086_2018_1495557
crossref_primary_10_1016_j_ctarc_2022_100527
crossref_primary_10_1371_journal_pone_0211228
crossref_primary_10_3389_fphar_2021_769315
crossref_primary_10_1016_j_cjca_2017_12_001
crossref_primary_10_1021_acs_jmedchem_9b01916
crossref_primary_10_1182_blood_2017_08_764712
crossref_primary_10_1080_17474086_2020_1728249
crossref_primary_10_1080_17474086_2020_1817735
crossref_primary_10_1080_13543784_2018_1482273
crossref_primary_10_1007_s10456_018_9621_x
crossref_primary_10_1007_s11886_023_01916_4
crossref_primary_10_1182_bloodadvances_2023012221
crossref_primary_10_1080_20009666_2018_1555432
crossref_primary_10_21320_2500_2139_2019_12_2_220_230
crossref_primary_10_3389_fphar_2024_1340855
crossref_primary_10_1002_hon_2545
crossref_primary_10_1182_blood_2019000840
crossref_primary_10_17650_1818_8346_2018_13_3_47_54
crossref_primary_10_1016_j_jaccao_2020_06_006
crossref_primary_10_3390_cancers14030771
crossref_primary_10_1136_openhrt_2019_001049
crossref_primary_10_1080_10428194_2021_1913139
crossref_primary_10_1080_17474086_2019_1597703
crossref_primary_10_1254_fpj_23094
crossref_primary_10_1080_10428194_2017_1375101
crossref_primary_10_1016_j_amjcard_2019_05_029
crossref_primary_10_1016_j_acvd_2023_02_005
crossref_primary_10_1016_j_jacep_2022_11_034
crossref_primary_10_1007_s11912_018_0694_x
crossref_primary_10_1080_10428194_2017_1339874
crossref_primary_10_5604_01_3001_0016_0698
crossref_primary_10_1016_j_critrevonc_2024_104408
crossref_primary_10_1111_ajco_13179
crossref_primary_10_1097_PPO_0000000000000412
crossref_primary_10_1016_j_jacadv_2023_100602
crossref_primary_10_3390_cancers11121834
crossref_primary_10_47671_TVG_77_21_068
crossref_primary_10_1111_echo_14946
crossref_primary_10_1200_JCO_21_00693
crossref_primary_10_1182_bloodadvances_2021005621
crossref_primary_10_2174_1573403X18666220531094800
crossref_primary_10_1080_14712598_2021_1889510
crossref_primary_10_1016_j_therap_2021_09_008
crossref_primary_10_1177_1073274820931808
crossref_primary_10_1080_10428194_2023_2278433
crossref_primary_10_3390_ph16010098
crossref_primary_10_1161_CIRCULATIONAHA_120_049210
crossref_primary_10_1016_j_jaccao_2020_10_001
crossref_primary_10_1080_14740338_2023_2204226
crossref_primary_10_1097_FJC_0000000000001182
crossref_primary_10_1155_2017_7304021
crossref_primary_10_36290_xon_2023_067
crossref_primary_10_30895_2312_7821_2020_8_4_178_190
crossref_primary_10_1161_JAHA_123_032357
crossref_primary_10_1016_j_jaccao_2024_02_006
crossref_primary_10_3390_curroncol30120764
crossref_primary_10_1007_s11912_017_0620_7
crossref_primary_10_15212_CVIA_2023_0070
crossref_primary_10_3390_jcm9092885
crossref_primary_10_1016_j_jaccao_2023_02_001
crossref_primary_10_2147_JEP_S265284
crossref_primary_10_1093_eurheartj_ehae222
crossref_primary_10_1016_j_jaccao_2021_01_009
crossref_primary_10_1161_CIRCEP_117_005443
crossref_primary_10_1002_acg2_51
crossref_primary_10_1182_blood_2018884940
crossref_primary_10_3390_biomedicines8110496
crossref_primary_10_1007_s00399_019_00634_1
crossref_primary_10_1182_asheducation_2017_1_354
crossref_primary_10_1002_hon_3145
crossref_primary_10_1161_JAHA_122_025786
crossref_primary_10_3389_fphar_2020_00891
crossref_primary_10_1080_10428194_2018_1533129
crossref_primary_10_1080_17474086_2020_1696185
crossref_primary_10_2217_fon_2017_0466
crossref_primary_10_1007_s11899_024_00731_0
crossref_primary_10_1056_NEJMoa1812836
crossref_primary_10_15420_aer_2023_24
crossref_primary_10_1186_s40959_021_00125_8
crossref_primary_10_1007_s00277_020_04094_3
crossref_primary_10_1080_10428194_2017_1375110
crossref_primary_10_1200_JOP_18_00592
crossref_primary_10_1080_14740338_2020_1802424
crossref_primary_10_1002_jha2_638
crossref_primary_10_1016_j_stemcr_2019_03_011
crossref_primary_10_1161_JAHA_121_022369
crossref_primary_10_1016_j_hrcr_2021_03_013
Cites_doi 10.1182/blood.V126.23.470.470
10.1182/blood.V126.23.4529.4529
10.1182/blood-2014-10-604272
10.1182/blood-2014-12-617522
10.1056/NEJMoa1501548
10.1093/eurheartj/ehi825
10.1161/01.CIR.96.6.1729
10.1182/blood.V126.23.1745.1745
10.1016/j.clml.2015.07.051
10.1182/blood.V126.23.2745.2745
10.1182/blood.V126.23.2935.2935
10.1016/S1470-2045(15)00465-9
10.1016/S0140-6736(15)00667-4
10.1182/blood.V126.23.2945.2945
10.1016/S1470-2045(15)00438-6
10.1182/blood.V126.23.2933.2933
10.1161/01.CIR.96.7.2455
10.1182/blood-2015-03-635326
10.1056/NEJMoa1400376
10.1056/NEJMoa1509388
10.1002/ajh.24366
10.1182/blood-2014-10-606038
10.1093/annonc/mdv111
ContentType Journal Article
Copyright 2016 American Society of Hematology
Copyright_xml – notice: 2016 American Society of Hematology
DBID 6I.
AAFTH
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
DOI 10.1182/blood-2016-05-712828
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Biology
Anatomy & Physiology
EISSN 1528-0020
EndPage 140
ExternalDocumentID 10_1182_blood_2016_05_712828
27247135
S0006497120343937
Genre Letter
Meta-Analysis
Review
Research Support, Non-U.S. Gov't
Systematic Review
GroupedDBID ---
-~X
.55
1CY
23N
2WC
34G
39C
4.4
53G
5GY
5RE
5VS
6I.
6J9
AAEDW
AAFTH
AAXUO
ABOCM
ABVKL
ACGFO
ADBBV
AENEX
AFOSN
AHPSJ
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BTFSW
CS3
DIK
DU5
E3Z
EBS
EJD
EX3
F5P
FDB
FRP
GS5
GX1
IH2
K-O
KQ8
L7B
LSO
MJL
N9A
OK1
P2P
R.V
RHF
RHI
ROL
SJN
THE
TR2
TWZ
W2D
W8F
WH7
WOQ
WOW
X7M
YHG
YKV
ZA5
0R~
0SF
AALRI
ADVLN
AFETI
AITUG
AKRWK
AMRAJ
CGR
CUY
CVF
ECM
EIF
H13
NPM
AAYXX
CITATION
ID FETCH-LOGICAL-c408t-d451cca0beca5ef56d77f4c2d229f708e11ea288a5431030f69adaa18f8cb103
IEDL.DBID ABVKL
ISSN 0006-4971
IngestDate Fri Dec 06 06:25:09 EST 2024
Sat Sep 28 08:26:13 EDT 2024
Fri Feb 23 02:45:00 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License This article is made available under the Elsevier license.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c408t-d451cca0beca5ef56d77f4c2d229f708e11ea288a5431030f69adaa18f8cb103
OpenAccessLink https://www.sciencedirect.com/science/article/pii/S0006497120343937
PMID 27247135
PageCount 3
ParticipantIDs crossref_primary_10_1182_blood_2016_05_712828
pubmed_primary_27247135
elsevier_sciencedirect_doi_10_1182_blood_2016_05_712828
PublicationCentury 2000
PublicationDate 2016-07-07
PublicationDateYYYYMMDD 2016-07-07
PublicationDate_xml – month: 07
  year: 2016
  text: 2016-07-07
  day: 07
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Blood
PublicationTitleAlternate Blood
PublicationYear 2016
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References Wang, Blum, Martin (bib15) 2015; 126
Ekman, Lymboussaki, Västrik, Sarvas, Kaipainen, Alitalo (bib25) 1997; 96
Parikh SA, Chaffee KR, Call TG, et al, Ibrutinib therapy for chronic lymphocytic leukemia (CLL): an analysis of a large cohort of patients treated in routine clinical practice [abstract]. Blood. 2015;126(23). Abstract 2935.
Romisher A, Carver J, Schuster SJ, et al, Bruton's tyrosine kinase inhibition is associated with manageable cardiac toxicity [abstract]. Blood. 2015;126(23). Abstract 4529.
Dreyling, Jurczak, Jerkeman (bib4) 2016; 387
Hansson L, Winqvist M, Asklid A, et al, Real-world results on ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): Data from 97 Swedish patients treated in a compassionate use program [abstract]. Blood. 2015;126(23). Abstract 1745.
Sandoval-Sus JD, Chavez JC, Dalia S, et al, Outcomes of patients with relapsed/refractory chronic lymphocytic leukemia after ibrutinib discontinuation outside clinical trials: a single institution experience [abstract]. Blood. 2015;126(23). Abstract 2945.
McMullen, Boey, Ooi, Seymour, Keating, Tam (bib24) 2014; 124
Cheah, Chihara, Romaguera (bib19) 2015; 26
Byrd, Furman, Coutre (bib7) 2015; 125
Chanan-Khan, Cramer, Demirkan (bib3) 2016; 17
Byrd, O'Brien, James (bib6) 2013; 369
Burger, Tedeschi, Barr (bib1) 2015; 373
Jaglowski, Jones, Nagar (bib13) 2015; 126
Heeringa, van der Kuip, Hofman (bib22) 2006; 27
Treon, Tripsas, Meid (bib5) 2015; 372
Farooqui M, Valdez J, Soto S, Bray A, Tian X, Wiestner A, Atrial fibrillation in CLL/SLL patients on ibrutinib [abstract]. Blood. 2015;126(23). Abstract 2933.
Dimopoulos MA, Trotman J, Tedeschi A, et al, Ibrutinib therapy in rituximab-refractory patients with Waldenström's macroglobulinemia: initial results from an international, multicenter, open-label phase 3 substudy (iNNOVATETM) [abstract]. Blood. 2015;126(23). Abstract 2745.
Fowler N, Nastoupil L, De Vos S, et al, Ibrutinib plus rituximab in treatment-naive patients with follicular lymphoma: results from a multicenter, phase 2 study [abstract]. Blood. 2015;126(23). Abstract 470.
Stilgenbauer, Jones, Coutre (bib12) 2015; 38
Gustine, Meid, Dubeau, Treon, Castillo (bib21) 2016; 91
Byrd, Brown, O'Brien (bib2) 2014; 371
Psaty, Manolio, Kuller (bib23) 1997; 96
O'Brien, Coutre, Furman (bib11) 2015; 15
Wang, Lee, Chuang (bib14) 2016; 17
Gustine (2019111903065316200_B21) 2016; 91
2019111903065316200_B20
Ekman (2019111903065316200_B25) 1997; 96
Heeringa (2019111903065316200_B22) 2006; 27
Psaty (2019111903065316200_B23) 1997; 96
Wang (2019111903065316200_B14) 2016; 17
O’Brien (2019111903065316200_B11) 2015; 15
2019111903065316200_B18
2019111903065316200_B16
2019111903065316200_B17
Stilgenbauer (2019111903065316200_B12) 2015; 38
2019111903065316200_B10
Jaglowski (2019111903065316200_B13) 2015; 126
Byrd (2019111903065316200_B2) 2014; 371
Wang (2019111903065316200_B15) 2015; 126
Burger (2019111903065316200_B1) 2015; 373
2019111903065316200_B9
Treon (2019111903065316200_B5) 2015; 372
2019111903065316200_B8
Cheah (2019111903065316200_B19) 2015; 26
Byrd (2019111903065316200_B7) 2015; 125
Byrd (2019111903065316200_B6) 2013; 369
McMullen (2019111903065316200_B24) 2014; 124
Dreyling (2019111903065316200_B4) 2016; 387
Chanan-Khan (2019111903065316200_B3) 2016; 17
References_xml – volume: 126
  start-page: 739
  year: 2015
  end-page: 745
  ident: bib15
  article-title: Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.
  publication-title: Blood
  contributor:
    fullname: Martin
– volume: 91
  start-page: E312
  year: 2016
  end-page: E313
  ident: bib21
  article-title: Atrial fibrillation associated with ibrutinib in Waldenström macroglobulinemia.
  publication-title: Am J Hematol
  contributor:
    fullname: Castillo
– volume: 17
  start-page: 48
  year: 2016
  end-page: 56
  ident: bib14
  article-title: Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.
  publication-title: Lancet Oncol
  contributor:
    fullname: Chuang
– volume: 38
  start-page: 92
  year: 2015
  ident: bib12
  article-title: Results from the phase 2 RESONATETM-17 trial: Efficacy and safety of Ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma with Del17p [abstract].
  publication-title: Oncol Res Treat
  contributor:
    fullname: Coutre
– volume: 126
  start-page: 842
  year: 2015
  end-page: 850
  ident: bib13
  article-title: Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.
  publication-title: Blood
  contributor:
    fullname: Nagar
– volume: 125
  start-page: 2497
  year: 2015
  end-page: 2506
  ident: bib7
  article-title: Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
  publication-title: Blood
  contributor:
    fullname: Coutre
– volume: 371
  start-page: 213
  year: 2014
  end-page: 223
  ident: bib2
  article-title: Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
  publication-title: N Engl J Med
  contributor:
    fullname: O'Brien
– volume: 15
  start-page: S23
  year: 2015
  ident: bib11
  article-title: Durable responses including complete responses in CLL following long term treatment with single-agent ibrutinib 420 mg [abstract].
  publication-title: Clin Lymphoma Myeloma Leuk
  contributor:
    fullname: Furman
– volume: 26
  start-page: 1175
  year: 2015
  end-page: 1179
  ident: bib19
  article-title: Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.
  publication-title: Ann Oncol
  contributor:
    fullname: Romaguera
– volume: 387
  start-page: 770
  year: 2016
  end-page: 778
  ident: bib4
  article-title: Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
  publication-title: Lancet
  contributor:
    fullname: Jerkeman
– volume: 373
  start-page: 2425
  year: 2015
  end-page: 2437
  ident: bib1
  article-title: Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
  publication-title: N Engl J Med
  contributor:
    fullname: Barr
– volume: 124
  start-page: 3829
  year: 2014
  end-page: 3830
  ident: bib24
  article-title: Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.
  publication-title: Blood
  contributor:
    fullname: Tam
– volume: 96
  start-page: 2455
  year: 1997
  end-page: 2461
  ident: bib23
  article-title: Incidence of and risk factors for atrial fibrillation in older adults.
  publication-title: Circulation
  contributor:
    fullname: Kuller
– volume: 27
  start-page: 949
  year: 2006
  end-page: 953
  ident: bib22
  article-title: Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study.
  publication-title: Eur Heart J
  contributor:
    fullname: Hofman
– volume: 17
  start-page: 200
  year: 2016
  end-page: 211
  ident: bib3
  article-title: Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
  publication-title: Lancet Oncol
  contributor:
    fullname: Demirkan
– volume: 369
  start-page: 1278
  year: 2013
  end-page: 1279
  ident: bib6
  article-title: Ibrutinib in relapsed chronic lymphocytic leukemia.
  publication-title: N Engl J Med
  contributor:
    fullname: James
– volume: 96
  start-page: 1729
  year: 1997
  end-page: 1732
  ident: bib25
  article-title: Bmx tyrosine kinase is specifically expressed in the endocardium and the endothelium of large arteries.
  publication-title: Circulation
  contributor:
    fullname: Alitalo
– volume: 372
  start-page: 1430
  year: 2015
  end-page: 1440
  ident: bib5
  article-title: Ibrutinib in previously treated Waldenström's macroglobulinemia.
  publication-title: N Engl J Med
  contributor:
    fullname: Meid
– ident: 2019111903065316200_B10
  doi: 10.1182/blood.V126.23.470.470
– ident: 2019111903065316200_B18
  doi: 10.1182/blood.V126.23.4529.4529
– volume: 124
  start-page: 3829
  issue: 25
  year: 2014
  ident: 2019111903065316200_B24
  article-title: Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.
  publication-title: Blood
  doi: 10.1182/blood-2014-10-604272
  contributor:
    fullname: McMullen
– volume: 126
  start-page: 842
  issue: 7
  year: 2015
  ident: 2019111903065316200_B13
  article-title: Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.
  publication-title: Blood
  doi: 10.1182/blood-2014-12-617522
  contributor:
    fullname: Jaglowski
– volume: 372
  start-page: 1430
  issue: 15
  year: 2015
  ident: 2019111903065316200_B5
  article-title: Ibrutinib in previously treated Waldenström’s macroglobulinemia.
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1501548
  contributor:
    fullname: Treon
– volume: 369
  start-page: 1278
  issue: 13
  year: 2013
  ident: 2019111903065316200_B6
  article-title: Ibrutinib in relapsed chronic lymphocytic leukemia.
  publication-title: N Engl J Med
  contributor:
    fullname: Byrd
– volume: 27
  start-page: 949
  issue: 8
  year: 2006
  ident: 2019111903065316200_B22
  article-title: Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study.
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehi825
  contributor:
    fullname: Heeringa
– volume: 96
  start-page: 1729
  issue: 6
  year: 1997
  ident: 2019111903065316200_B25
  article-title: Bmx tyrosine kinase is specifically expressed in the endocardium and the endothelium of large arteries.
  publication-title: Circulation
  doi: 10.1161/01.CIR.96.6.1729
  contributor:
    fullname: Ekman
– ident: 2019111903065316200_B20
  doi: 10.1182/blood.V126.23.1745.1745
– volume: 15
  start-page: S23
  issue: suppl 2
  year: 2015
  ident: 2019111903065316200_B11
  article-title: Durable responses including complete responses in CLL following long term treatment with single-agent ibrutinib 420 mg [abstract].
  publication-title: Clin Lymphoma Myeloma Leuk
  doi: 10.1016/j.clml.2015.07.051
  contributor:
    fullname: O’Brien
– ident: 2019111903065316200_B8
  doi: 10.1182/blood.V126.23.2745.2745
– ident: 2019111903065316200_B16
  doi: 10.1182/blood.V126.23.2935.2935
– volume: 17
  start-page: 200
  issue: 2
  year: 2016
  ident: 2019111903065316200_B3
  article-title: Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(15)00465-9
  contributor:
    fullname: Chanan-Khan
– volume: 387
  start-page: 770
  issue: 10020
  year: 2016
  ident: 2019111903065316200_B4
  article-title: Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
  publication-title: Lancet
  doi: 10.1016/S0140-6736(15)00667-4
  contributor:
    fullname: Dreyling
– ident: 2019111903065316200_B17
  doi: 10.1182/blood.V126.23.2945.2945
– volume: 17
  start-page: 48
  issue: 1
  year: 2016
  ident: 2019111903065316200_B14
  article-title: Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(15)00438-6
  contributor:
    fullname: Wang
– ident: 2019111903065316200_B9
  doi: 10.1182/blood.V126.23.2933.2933
– volume: 96
  start-page: 2455
  issue: 7
  year: 1997
  ident: 2019111903065316200_B23
  article-title: Incidence of and risk factors for atrial fibrillation in older adults.
  publication-title: Circulation
  doi: 10.1161/01.CIR.96.7.2455
  contributor:
    fullname: Psaty
– volume: 126
  start-page: 739
  issue: 6
  year: 2015
  ident: 2019111903065316200_B15
  article-title: Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.
  publication-title: Blood
  doi: 10.1182/blood-2015-03-635326
  contributor:
    fullname: Wang
– volume: 38
  start-page: 92
  issue: suppl 5
  year: 2015
  ident: 2019111903065316200_B12
  article-title: Results from the phase 2 RESONATETM-17 trial: Efficacy and safety of Ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma with Del17p [abstract].
  publication-title: Oncol Res Treat
  contributor:
    fullname: Stilgenbauer
– volume: 371
  start-page: 213
  issue: 3
  year: 2014
  ident: 2019111903065316200_B2
  article-title: Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1400376
  contributor:
    fullname: Byrd
– volume: 373
  start-page: 2425
  issue: 25
  year: 2015
  ident: 2019111903065316200_B1
  article-title: Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1509388
  contributor:
    fullname: Burger
– volume: 91
  start-page: E312
  issue: 6
  year: 2016
  ident: 2019111903065316200_B21
  article-title: Atrial fibrillation associated with ibrutinib in Waldenström macroglobulinemia.
  publication-title: Am J Hematol
  doi: 10.1002/ajh.24366
  contributor:
    fullname: Gustine
– volume: 125
  start-page: 2497
  issue: 16
  year: 2015
  ident: 2019111903065316200_B7
  article-title: Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
  publication-title: Blood
  doi: 10.1182/blood-2014-10-606038
  contributor:
    fullname: Byrd
– volume: 26
  start-page: 1175
  issue: 6
  year: 2015
  ident: 2019111903065316200_B19
  article-title: Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdv111
  contributor:
    fullname: Cheah
SSID ssj0014325
Score 2.6144724
SecondaryResourceType review_article
SourceID crossref
pubmed
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 138
SubjectTerms Agammaglobulinaemia Tyrosine Kinase
Animals
Atrial Fibrillation - chemically induced
Atrial Fibrillation - etiology
Humans
Incidence
Leukemia - drug therapy
Lymphoma - drug therapy
Protein Kinase Inhibitors - adverse effects
Protein Kinase Inhibitors - therapeutic use
Protein-Tyrosine Kinases - antagonists & inhibitors
Pyrazoles - adverse effects
Pyrazoles - therapeutic use
Pyrimidines - adverse effects
Pyrimidines - therapeutic use
Title The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis
URI https://dx.doi.org/10.1182/blood-2016-05-712828
https://www.ncbi.nlm.nih.gov/pubmed/27247135
Volume 128
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3LSsNAcKgtPi6i9VVf7EG8hSbbTbLxVotSrAqCip7CJrsLBY2i9eDfO5Pd-LgoeAsDuxtmhnk_AA60GKAWinlgImUDkWgRFEail1IklqZ5C2OoOfniMhnfiLO7-K4Fo6YXhsoqvex3Mr2W1h7S99jsP0-n1OOL6jRLIx4OBI11m4MOzTJH1u4Mj28n55_JBDHgbpEBOs90wHfQoWXdd9XhqAQTygjjXZLWsv-qob6pn9MVWPZ2Ixu6X1uFlqm6sDas0Gd-fGeHrK7krEPkXZg_br4WR80-ty4sXPg0-hrcI3MwKipnT5apenEHs1T7_-Aq4xhFZxkCkCuracHeXs0RU-xr6jNzHS9MVZo9mpkKlJ9tsg7XpyfXo3HgdywEpQjlLNAijpCIIZJSxcbGiU5TK0quOc9sGkoTRUZxKRX1zKNAsEmmtFKRtLIsELAB7eqpMlvAVJlpFBdCanJyCpNFSlubiriMQ1vapAdBg9b82U3SyGsPRPK8JkNOZMjDOHdk6EHa4D7_wRE5Cvs_Tm46Un2-w1MuaBfh9r_v3IElxyUU2N2F9uzlzeyhOTIr9j277cPc5Ep-AOHT3QQ
link.rule.ids 314,780,784,27569,27924,27925,45663
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR27TsMw8FRAPBYE5f30gNiiJq6TOGylAhXaMhVUJsuJbakSDQjKwN9zjp0CC0hs0Um2o7vTvR8AZ4q1UQvFNNCRNAFLFAtyzdFLyRNjp3kzrW1z8vAu6d2z23E8bkC37oWxZZVe9juZXklrD2l5bLZeJhPb44vqNEsjGraZHeu2AEtoDSTI7Eudy4f-YJ5MYG3qFhmg82wP-A46tKxbrjoclWBiM8J4F7dr2X_VUN_Uz_UGrHu7kXTcr21CQ5dN2OqU6DNPP8g5qSo5qxB5E5Yv66_Vbr3PrQkrQ59G34JHZA5ii8rJsyGyWtxBjK39f3KVccRGZwkCkCvLSU7e3_QFkeRr6jNxHS9ElopM9UwG0s822YbR9dWo2wv8joWgYCGfBYrFERIxRFLKWJs4UWlqWEEVpZlJQ66jSEvKubQ98ygQTJJJJWXEDS9yBOzAYvlc6j0gssgUigvGlXVycp1FUhmTsriIQ1OYZB-CGq3ixU3SEJUHwqmoyCAsGUQYC0eGfUhr3IsfHCFQ2P9xcteRav4OTSmzuwgP_n3nKaz2RsOBGNzc9Q9hzXGMDfIeweLs9V0fo2kyy088630CGsbe9A
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+risk+of+atrial+fibrillation+with+ibrutinib+use%3A+a+systematic+review+and+meta-analysis&rft.jtitle=Blood&rft.au=Leong%2C+Darryl+P.&rft.au=Caron%2C+Fran%C3%A7ois&rft.au=Hillis%2C+Christopher&rft.au=Duan%2C+Annie&rft.date=2016-07-07&rft.pub=Elsevier+Inc&rft.issn=0006-4971&rft.eissn=1528-0020&rft.volume=128&rft.issue=1&rft.spage=138&rft.epage=140&rft_id=info:doi/10.1182%2Fblood-2016-05-712828&rft.externalDocID=S0006497120343937
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-4971&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-4971&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-4971&client=summon